Christian Schubert
Vice President & Global Head, AbbVie Ventures | Corporate Venture Capital in Immunology, Oncology & Neuroscience
Christian Schubert is Vice President and Global Head of AbbVie Ventures, the strategic venture arm of AbbVie. He leads the fund’s investing across immunology, oncology and neuroscience, with growth areas in respiratory disease, neuropsychiatry, pain and migraine. Roughly 80% of the fund’s annual capital goes into pre-seed through Series B rounds, under a first-in-class only mandate.
He trained as a scientist and intended an academic career before moving into pharmaceutical R&D, then diligence teams, then corporate strategy and external innovation, and then operating and founding roles inside small companies. In 2026 he launched AbbVie Ventures’ venture partner program, which embeds R&D scientists with twenty and thirty years of experience directly into the fund’s deal flow and portfolio companies.
Schubert appeared on Open Door Salon in September 2026 alongside Mike Goguen, founder and managing partner of Two Bear Capital. The conversation covered what separates a funded biotech pitch from a passed one: how a fund that reviewed roughly six hundred investable opportunities in a year arrived at five investments, what loses a pitch inside the first twenty minutes, whether warm introductions still move a founder to the front of the line, and why a rejection is sometimes a function of where a fund is in its own deployment cycle.
Frequently Asked Questions About Christian Schubert
Who is Christian Schubert?
Christian Schubert is Vice President and Global Head of AbbVie Ventures, the strategic venture arm of AbbVie. He trained as a scientist and intended an academic career before moving into pharmaceutical R&D, then diligence teams, then corporate strategy and external innovation, and then operating and founding roles inside small companies.
What does Christian Schubert invest in?
Christian Schubert leads AbbVie Ventures’ investing across immunology, oncology and neuroscience, with growth areas in respiratory disease, neuropsychiatry, pain and migraine. Roughly 80% of the fund’s annual capital goes into pre-seed through Series B rounds under a first-in-class only mandate.
How does Christian Schubert approach early-stage biotech investing?
Christian Schubert concentrates diligence on the middle of the market. On Open Door Salon he said “the real opportunity, and this is where the five came from, are in the middle”, describing the band of companies that show enough promise to warrant weeks of deeper work. He also keeps conversations open with founders his fund passes on, an approach he calls “the no but”.
What is AbbVie Ventures, the fund Christian Schubert leads?
Christian Schubert leads AbbVie Ventures, the strategic venture arm of AbbVie, as Vice President and Global Head. In 2026 he launched its venture partner program, which embeds R&D scientists with twenty and thirty years of experience directly into the fund’s deal flow and portfolio companies.
On Open Door Salon
“Mike Goguen and Christian Schubert on What Gets a Biotech Pitch Funded”
Mike Goguen & Christian Schubert · September 16, 2026
Episode page & show notes on Open Door Salon
In this episode
- Out of 600 opportunities, five investments. What the five had.
- The five to ten percent in the middle, where the work is
- Passion, resilience, and the North Star nobody else believes yet
- The capital gap corporate venture is stepping into
- What loses a pitch in the first twenty minutes
- How much diligence goes into the team, not just the founder
- Social worker and fireman: what early stage leadership actually is
- Do warm introductions still move you to the front of the line?
- Why raising less money early correlates with bigger outcomes
- The anatomy of a useful no
- The fund dynamics hiding behind a rejection
Topics
Watch on Open Door Salon
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →